Post kidney transplantation Kaposi's sarcoma: the experience of a Mediterranean North African center

2016 ◽  
Vol 30 (4) ◽  
pp. 372-379 ◽  
Author(s):  
Imen Gorsane ◽  
Mohamed Mongi Bacha ◽  
Ezzedine Abderrahim ◽  
Nadia Amri ◽  
Malika Hajri ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
North African

scholarly journals WHAT IS THE ROLE OF HHV 8 IN ETIOPATHOGENESIS OF KAPOSI'S SARCOMA OCCURRED AFTER KIDNEY TRANSPLANTATION?

1998 ◽  
Vol 65 (12) ◽  
pp. S149
Author(s):  
A. T??th ◽  
J. J??ray ◽  
D. G??r??g ◽  
K. Nagy ◽  
B. Szende ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma

Treatment of Kaposi's sarcoma after solid organ transplantation.

1997 ◽  
Vol 15 (6) ◽  
pp. 2371-2377 ◽  
Author(s):  
F A Shepherd ◽  
E Maher ◽  
C Cardella ◽  
E Cole ◽  
P Greig ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Organ Transplantation ◽  
Combination Chemotherapy ◽  
Kaposi's Sarcoma ◽  
Solid Organ Transplantation ◽  
Kaposi’S Sarcoma ◽  
Skin Toxicity ◽  
Solid Organ ◽  
Duration Of Response ◽  
Italian Origin

PURPOSE This retrospective review of all patients who developed Kaposi's sarcoma (KS) after solid organ transplantation at a single institution was undertaken to define the clinical presentation of this malignancy in the setting of iatrogenic immunodeficiency, and to determine the most appropriate treatment for patients in this clinical setting. MATERIALS AND METHODS The records of 2,099 patients who underwent heart, lung, liver, or kidney transplantation at The Toronto Hospital between January 1, 1981 and June 30, 1995, were reviewed. Twelve patients were identified who developed biopsy-proven KS in the posttransplantation period. Five patients who had disseminated KS who had not responded to either reduction or withdrawal of immunosuppression or to local radiotherapy were treated with combination chemotherapy consisting of doxorubicin 20 to 30 mg/m2, bleomycin 10 mg/m2, and vincristine 2 mg (ABV) administered intravenously every 3 weeks. RESULTS Eight of 12 patients were male and nine were of Italian origin. KS was limited to a localized area of the skin for only six patients, all after kidney transplantation. Visceral KS was present in three patients. Four of five patients responded to ABV chemotherapy (two complete and two partial remissions). The fifth patient responded to second-line etoposide and cisplatin. The median duration of response was in excess of 13 months (range, 8+ to 45+ months). Toxicity was limited to grade 1 neurotoxicity and grade 1 skin toxicity. CONCLUSION KS is an uncommon but recognized complication of solid organ transplantation. Combination chemotherapy is a safe and effective treatment for patients with disseminated or visceral KS that fails to respond to changes in immunosuppression.

Kidney transplantation and kaposi’s sarcoma: review of 2050 recipients

2001 ◽  
Vol 33 (5) ◽  
pp. 2818 ◽  
Author(s):  
M Lessan-Pezeshki ◽  
B Einollahi ◽  
M.R Khatami ◽  
M Mahdavi
Keyword(s):  
Kidney Transplantation ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma

scholarly journals Kaposi's sarcoma occurring in a young black man after kidney transplantation

2005 ◽  
Vol 20 (12) ◽  
pp. 2839-2841
Author(s):  
Antonietta De Blasio ◽  
Giuseppe Palmiero ◽  
Domenico Russo
Keyword(s):  
Kidney Transplantation ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Black Man

Immunosuppressive therapy and kaposi's sarcoma after kidney transplantation

2004 ◽  
Vol 36 (1) ◽  
pp. 168-170 ◽  
Author(s):  
G Moray ◽  
Ö Başaran ◽  
M.C Yağmurdur ◽  
R Emiroğlu ◽  
N Bilgin ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Immunosuppressive Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma

scholarly journals EVEROLIMUS FOR KAPOSI'S SARCOMA TREATMENT AFTER KIDNEY TRANSPLANTATION

2015 ◽  
Vol 17 (2) ◽  
pp. 60-63
Author(s):  
I. V. Alexandrov ◽  
V. A. Molochkov ◽  
A. D. Perlina ◽  
A. D. Sapozhnikov ◽  
O. V. Zhirkova ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Serum Creatinine ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Skin Lesions ◽  
Kidney Transplant Recipients ◽  
Moderate Growth ◽  
Increased Risk ◽  
Tacrolimus Therapy ◽  
Heart Donor

Materials.The forty five y.o. man with ESRD had underwent kidney transplantation from cadaveric 31 y.o. non biting heart donor 02.04.2013. He has received standard immunosupression: MP+Tc+MMF and for 4 weeks was discharged from hospital with serum creatinine 0.25 mmol/1. On the fifth post transplant month the patient discovered on the face skin multiple tumors. The tumors had moderate growth during next month. Kaposi's sarcoma had been proven by biopsy, so we stopped tacrolimus therapy in the recipient and started everolimus treatment. During next month there was no new skin lesions and the previously registered tumors had no futher growth. From that time we have seen gradual regression of skin lesions. We support everolimus blood level 4–8 ng/ml. month of the everolimus therapy proteinuria was appeared in the patient approximately 0.5– 0.7 g per day. The next month proteinuria increased till 1.8–2.4 g per day. The daily metilprednizolon dose was increased since 4 till 10 mg. The proteinuria decreased till 0.5–0.6 g per day. The kidney function during all period was stable with serum creatinine 0.22–0.26 mmol/1.Conclusion.Everolimus treatment with simultaneous calcinevrine inhibitors withdrawn offers a promising approach to the management of Kaposi's sarcoma in kidney transplant recipients without an increased risk of acute rejection.

IMMUNOSUPPRESSIVE THERAPY AND KAPOSI'S SARCOMA AFTER KIDNEY TRANSPLANTATION

2002 ◽  
Vol 60 (6) ◽  
pp. 558-558 ◽  
Author(s):  
M Haberal ◽  
G Moray ◽  
T Çolak ◽  
MC Yagmurdur
Keyword(s):  
Kidney Transplantation ◽  
Immunosuppressive Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma
Sign in / Sign up

Export Citation Format

Share Document